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ABSTRACT
Western populations have a growing obesity epidemic due in part to 
excessive nutrient intake from high-fat diets, which are increasingly 
common. Overindulgence of nutrients is associated with a greater 
incidence of metabolic dysfunction and a greater risk for obesity, 
diabetes, hypertension, and other metabolic disorders that lower 
quality of life. Research in humans and animal models has improved 
our understanding of how excess circulating free fatty acids negatively 
impact the ability of muscle and other tissues to regulate nutrient 
uptake and utilization. It is generally accepted by the scientific 
community that excess circulating fatty acids lead to insulin resistance, 
but there is little clarity regarding the underlying mechanisms. In 
the present review, we will outline the current understanding of the 
characteristics associated with fatty acid mobilization and fatty acid 
utilization within specific tissues. We will also discuss the potential 
mechanistic role of hyperlipidemia on metabolic dysfunction associated 
with type 2 diabetes.
INTRODUCTION
Epidemiological studies have identified metabolic 
disorders and heart disease as health consequences 
resulting from obesity in US and global popula-
tions.1 Greater accumulation of adipose tissue is 
associated with physiological pathologies such as 
hyperlipidemia, chronic inflammation, and insulin 
resistance.2 A primary factor in these metabolic 
pathologies is elevated circulating free fatty acids 
(FFA), which is a common characteristic of obese 
individuals and type 2 diabetics.2 High blood FFA 
concentrations lead to reduced whole-body glucose 
uptake and oxidation rates and also decrease skele-
tal muscle glycogen synthase.3 However, fatty acids 
are also important components of complex lipids 
that are necessary for structural and functional 
integrity of cellular membranes. Due to the cyto-
toxic nature of FFA,4 lipolytic enzymes tightly regu-
late mobilization of fatty acids from triglycerides 
stored within adipose tissue.4 Consequently, 
enzymatic dysfunction contributes to pathologies 
underlying the development of obesity and insulin 
resistance, although metabolic factors, genetics, 
and environment also play roles.5,6 Prolonged peri-
ods of elevated circulating FFA concentrations lead 
to impaired hepatic lipoprotein production, poor 
insulin responsiveness in skeletal muscle and liver, 
and pancreatic β-cell dysfunction independent of 
body composition.7 Recent studies have further 
characterized FFA-induced pathologies by identi-
fying receptors and signaling pathways involved in 
the underlying mechanisms,8,9 as detailed in later 
sections. This fundamental research has increased 
our understanding of the role of high circulating 
FFA in pathologies associated with obesity and type 
2 diabetes. In this review, we describe the mecha-
nisms by which disruption of fatty acid mobiliza-
tion, skeletal muscle fatty acid utilization, and FFA 
homeostasis result in metabolic pathologies and 
disorders that reduce life span and lower quality of 
life.
MECHANISM OF FATTY ACID 
MOBILIZATION
In mammals, excess energy substrates are stored 
as triglycerides in adipose tissue and can be 
mobilized to maintain a balance of stored and 
circulating lipid concentrations.5 Storage, synthe-
sis, and utilization of adipose triglycerides is 
regulated by hormonal and paracrine factors in 
response to changing blood FFA concentrations.5 
Circulating FFA concentrations are determined 
by the rate at which they are mobilized and enter 
circulation combined with the rate at which they 
are cleared and deposited into adipose tissue, as 
illustrated in Figure 1. Fatty acid mobilization 
typically increases when the body enters into a 
hypoglycemic state due to fasting or an increase 
in adrenergic stimulation.10 Catecholamines from 
the sympathetic nervous system or the adrenal 
medulla are the primary stimulants of fatty acid 
mobilization, especially in response to stress 
conditions.10 Catecholamines directly affect fat 
cells via G protein-coupled receptors. Binding of β 
or α2 adrenergic receptors on adipocytes activates 
the signaling cascades illustrated in Figure 2 that 
stimulate adenylate cyclase-mediated increases 
in cyclic adenosine 3, 5-monophosphate (cAMP) 
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which in turn activates cAMP-dependent protein 
kinase A (PKA).5,7,11 Active PKA phosphorylates 
hormone sensitive lipase (HSL) that then catabo-
lizes triglycerides stored within the adipocyte.7,12 In 
the cytosol, adipose triglyceride lipase (ATGL) and 
HSL adhere to lipid droplets to facilitate hydrolysis 
of triglycerides.13 Perilipin A, a structural protein 
located on the surface of lipid droplets, then medi-
ates the release of fatty acids into circulation.5,7,12 
Excessive fatty acid accumulation can be cytotoxic 
and therefore uptake and storage of fatty acids is 
tightly regulated.7,12 Once fatty acids are inside 
the cell, cytosolic fatty acid binding proteins and 
transport proteins chaperone fatty acids to the 
mitochondria to be metabolized for energy via 
β-oxidation.9,14 Dysfunctional mobilization often 
results in greater postprandial FFA plasma concen-
trations, which is a hallmark characteristic of indi-
viduals with type 2 diabetes. 
FATTY ACID ACCUMULATION IN 
SKELETAL MUSCLE TISSUE
The mechanism by which fatty acids impair insu-
lin-stimulated glucose oxidation in skeletal muscle 
has been described.3,15,16 Furthermore, studies 
have elucidated that the triglyceride content of 
muscle has a negative relationship with whole-
body insulin sensitivity. Pan et  al.17 performed 
hyperinsulinemic-euglycemic clamp studies on 
non-diabetic, overweight adult males to determine 
whole-body insulin sensitivity and then analyzed 
vastus lateralis biopsies for triglyceride content. 
Their results showed a negative correlation between 
the two. In order to further explain this relation-
ship, in vivo studies18,19 have investigated how 
the source of triglycerides affects skeletal muscle 
insulin resistance by isolating extramyocellular 
and intramyocellular lipid fractions.18-21 Krssak 
et  al.22 characterized the negative relationship of 
intramyocellular lipid fractions on whole body 
glucose uptake by demonstrating that intramyocel-
lular stores are primarily responsible for increasing 
skeletal muscle insulin resistance. These discoveries 
helped subsequent investigators clarify the role 
of other cellular components by identifying and 
isolating receptors and intracellular intermediates 
associated with FFA accumulation and insulin 
resistance, with initial focus on glucose oxidation. 
Indeed, early research has shown that FFA concen-
trations and glucose metabolism impact each 
other,15,23,24 and more recent studies have begun to 
identify the intracellular axes and gene transcripts 
involved.8,9,14 
FFA are transported from blood into skeletal 
muscle cells using fatty acid binding proteins 
(FABP) and fatty acid transport proteins (FATP). 
Collectively, there are a number of members of 
the FATP family that include FATP1, FATP4, and 
FATP6.14 In addition to FFA transport, these FATP 
may have acyl-CoA synthetase enzymatic activity, 
which activates FFA for metabolism.9 FATP1 is 
the most prevalent transport protein expressed 
by skeletal muscle.14 It has a central role in fatty 
acid transport in T-tubules and it increases FFA 
Figure 1  Concentrations of free fatty acids (FFA) in the bloodstream are 
determined by the combined rates at which they are mobilized / 
secreted into circulation and cleared from circulation.
Figure 2  Catecholamines stimulate fatty acid mobilization from adipo-
cytes. Binding of β or α2 adrenergic G protein-coupled receptors 
activates second messenger signal cascades that include adenylate 
cyclase-mediated increases in cyclic adenosine 3, 5-monophos-
phate (cAMP), activated cAMP-dependent protein kinase A (PKA), 
phosphorylated hormone sensitive lipase (HSL), and ultimately 
catabolized triglycerides. Adipose triglyceride lipase (ATGL) and 
HSL facilitate hydrolysis of triglycerides, and Perilipin A mediates 
FFA secretion. FFA travel in circulation bound to carrier proteins.
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oxidation in response to insulin stimulation.14 
However, when FFA uptake occurs at a faster rate 
than FFA oxidation, it causes an accumulation of 
lipid intermediates that results in lipotoxic stress.25 
Lipotoxicity results from excess intramyocellular 
buildup of triacylglycerol, diacylglycerol, long-
chain acyl CoA, and ceramides. The mechanism 
is not fully understood, but elevated lipid inter-
mediates such as ceramides and diacylglycerol 
appear to impair insulin signaling in skeletal 
muscle.8 Ceramides are generated through a de 
novo pathway via condensation of palmitoyl CoA 
and serine.8 Ceramides are elevated in diabetic 
patients and inhibit a number of protein kinases, 
which are otherwise stimulated by insulin. They 
also likely activate the atypical protein kinase C 
isoforms within insulin-responsive tissues.13 This 
represents one potential mechanistic outcome 
whereby dysfunctional FFA mobilization and the 
resulting accumulation contribute to the devel-
opment of skeletal muscle insulin resistance. In 
contrast, research has demonstrated that elevated 
triacylglycerol content in skeletal muscle is 
common among high-endurance athletes despite 
adequate hydrolysis of FFA.13 Individuals who 
undergo endurance training also have elevated 
ATGL expression in skeletal muscle cells, which 
is associated with increased oxidative capacity.13 
Due to the increased energy demand of these 
athletes, increased lipolysis presumably helps fuel 
the requirements for their bodies’ work output. 
Therefore, increased levels of circulating triacyl-
glycerol in endurance athletes are understandable; 
however, further research is needed to identify 
what mechanisms are involved in maintaining 
insulin sensitivity in these individuals.
HEPATIC LIPID METABOLISM
The liver is a major regulator of lipid flux and plays 
a crucial role in maintaining FFA blood plasma 
concentrations.26 Hepatic FFA accumulation can 
occur as a consequence of decreased FFA oxidation, 
excessive FFA liberation from lipolyzed adipose 
triglycerides, inadequate triacylglycerol excretion, 
or hepatic de novo lipogenesis.26 Greater hepatic fat 
content from any of these mechanisms can contrib-
ute to the development of insulin resistance and 
type 2 diabetes.27 Most FFA taken up from circula-
tion by the liver had entered the bloodstream after 
being mobilized from adipose tissue.26 The nuclear 
receptor peroxisome proliferator-activated receptor 
alpha (PPARα) senses the hepatic influx of circu-
lating FFA and upregulates gene expression of fatty 
acid oxidative systems.28 The lab of JK Reddy28-31 
identified this regulation mechanism by knock-
ing out the genes for PPARα and fatty acyl-CoA 
oxidase (ACOX) in mice. These mice were conse-
quently unable to upregulate genes associated with 
fatty acid oxidation systems, and the subsequent 
increase in triglyceride synthesis contributed to the 
development of liver steatosis.28-31 Mitochondrial 
β-oxidation is a complex process that is regulated 
in part by enzymatic activity of carnitine palmito-
yltransferase 1 and by concentrations of carnitine 
and malonyl-CoA. For β-oxidation to occur, intra-
cellular FFA must first be activated into esters by 
acyl-CoA synthetase in order to enter the mito-
chondrial β-oxidation spiral.31 Downregulation of 
ACOX in the liver damages this transport system 
and thus decreases FFA oxidation within the cell.31 
Regardless of the tissue, proper regulation and 
balance of FFA mobilization and oxidation is crit-
ical to maintain.
FATTY ACID-INDUCED PANCREATIC 
Β-CELL DYSFUNCTION
Ex vivo studies have shown that prolonged expo-
sure of rat pancreatic islets to elevated FFA concen-
trations decreases glucose-stimulated insulin 
secretion.32,33 The impact of elevated circulating 
FFA concentrations on human β-cell function is 
less clear, as insulin secretion was increased after 
6-hour FFA infusion but decreased after 24 hours 
in non-obese healthy individuals.34 When indi-
viduals were made chronically hyperglycemic, 
however, insulin secretion was increased by FFA 
infusion for 48 hours.35 Nevertheless, lipotoxicity is 
a potential source of β-cell injury in patients with 
type 2 diabetes.36 Deleterious effects on β-cells from 
prolonged exposure to high FFA concentrations are 
indicated by studies showing inhibition of insulin 
mRNA expression and increased ceramide produc-
tion that led to nitric oxide-dependent cell death.36 
Increased accumulation of islet amyloid after FFA 
exposure causes islet amyloidosis and inflamma-
tion.37 Amyloid deposition is associated with less 
islet volume due to a reduction in β-cell mass.38 
It is important to note that some individual fatty 
acids such as palmitate can actually suppress β-cell 
dysfunction and demise,39,40 since these saturated 
fatty acids act as inhibitors of pyruvate carboxylase 
activity.41 It is clear that research has only begun 
to uncover how FFA concentrations impact β-cell 
function independent from fat mass. However, we 
have a better understanding of how these energy 
intermediates contribute to impaired insulin secre-
tion and function in type 2 diabetes.
CONCLUSION
Dysregulation of fatty acid storage, mobilization, 
and metabolism is implicit in a number of metabolic 
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diseases. It is becoming clear that the loss of free 
fatty acid homeostasis is at least partially indepen-
dent of obesity, which furthers our understanding 
of the fatty acid cycle and its role in metabolic 
disease. However further research is warranted to 
elucidate the mechanistic details of these changes 
in fatty acid flux in order to address the growing 
global metabolic syndrome epidemic. Exploration 
of transcriptional modifications, understanding 
and isolating mechanisms underlying the “athlete 
phenomenon,” and developing the basis for FFA 
therapies are fundamental steps in providing a 
better understanding of the interactive role that 
FFA flux plays in metabolic disease and improving 
outcomes in these individuals. 
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